- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
- You can view the full Goldman Sachs Group Ratings Report.
Holding back the Dow today is Pfizer (NYSE: PFE), which is lagging the broader Dow index with a 56-cent decline (-1.9%) bringing the stock to $29.62. This single loss is lowering the Dow Jones Industrial Average by 4.24 points or roughly accounting for 17.7% of the Dow's overall loss. Volume for Pfizer currently sits at 2.4 million shares traded vs. an average daily trading volume of 23 million shares.Pfizer has a market cap of $192.76 billion and is part of the health care sector and drugs industry. Shares are down 1.5% year-to-date as of Monday's close. The stock's dividend yield sits at 3.4%. Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Pfizer Ratings Report.